NeuroPace (NPCE) Competitors $9.14 -0.01 (-0.11%) Closing price 04:00 PM EasternExtended Trading$9.26 +0.13 (+1.37%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NPCE vs. PLSE, MDXG, KMTS, INMD, IRMD, EMBC, TNDM, AXGN, BBNX, and SIBNShould you be buying NeuroPace stock or one of its competitors? The main competitors of NeuroPace include Pulse Biosciences (PLSE), MiMedx Group (MDXG), Kestra Medical Technologies (KMTS), InMode (INMD), iRadimed (IRMD), Embecta (EMBC), Tandem Diabetes Care (TNDM), AxoGen (AXGN), Beta Bionics (BBNX), and SiBone (SIBN). These companies are all part of the "medical equipment" industry. NeuroPace vs. Its Competitors Pulse Biosciences MiMedx Group Kestra Medical Technologies InMode iRadimed Embecta Tandem Diabetes Care AxoGen Beta Bionics SiBone Pulse Biosciences (NASDAQ:PLSE) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends. Which has more volatility & risk, PLSE or NPCE? Pulse Biosciences has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Do analysts prefer PLSE or NPCE? Pulse Biosciences currently has a consensus price target of $22.00, suggesting a potential upside of 45.60%. NeuroPace has a consensus price target of $16.60, suggesting a potential upside of 81.62%. Given NeuroPace's higher possible upside, analysts clearly believe NeuroPace is more favorable than Pulse Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulse Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00NeuroPace 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Do insiders & institutionals hold more shares of PLSE or NPCE? 77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 71.5% of Pulse Biosciences shares are held by company insiders. Comparatively, 20.5% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor PLSE or NPCE? In the previous week, NeuroPace had 6 more articles in the media than Pulse Biosciences. MarketBeat recorded 6 mentions for NeuroPace and 0 mentions for Pulse Biosciences. NeuroPace's average media sentiment score of 1.48 beat Pulse Biosciences' score of 1.36 indicating that NeuroPace is being referred to more favorably in the news media. Company Overall Sentiment Pulse Biosciences Positive NeuroPace Positive Is PLSE or NPCE more profitable? Pulse Biosciences has a net margin of 0.00% compared to NeuroPace's net margin of -29.29%. Pulse Biosciences' return on equity of -63.19% beat NeuroPace's return on equity.Company Net Margins Return on Equity Return on Assets Pulse BiosciencesN/A -63.19% -54.98% NeuroPace -29.29%-168.61%-25.48% Which has stronger earnings and valuation, PLSE or NPCE? NeuroPace has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPulse Biosciences$700K1,452.29-$53.58M-$1.05-14.39NeuroPace$88.57M3.41-$27.14M-$0.84-10.88 SummaryNeuroPace beats Pulse Biosciences on 11 of the 16 factors compared between the two stocks. Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NPCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NPCE vs. The Competition Export to ExcelMetricNeuroPaceMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$302.36M$6.75B$5.69B$9.68BDividend YieldN/A1.19%6.66%4.54%P/E Ratio-10.8825.3882.6526.40Price / Sales3.4163.57498.44197.40Price / CashN/A22.4425.7028.92Price / Book33.854.8911.246.06Net Income-$27.14M$174.79M$3.28B$266.05M7 Day Performance1.90%-0.18%0.15%-0.07%1 Month Performance1.67%3.72%8.34%5.83%1 Year Performance15.40%6.49%54.21%17.88% NeuroPace Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NPCENeuroPace3.8115 of 5 stars$9.14-0.1%$16.60+81.6%+15.5%$302.36M$88.57M-10.88170News CoveragePositive NewsGap DownPLSEPulse Biosciences3.9857 of 5 stars$16.49-3.3%$22.00+33.4%-16.6%$1.15B$700K-15.70140MDXGMiMedx Group3.401 of 5 stars$7.08-3.1%$12.00+69.5%+3.8%$1.08B$348.88M33.72870News CoveragePositive NewsKMTSKestra Medical Technologies1.3076 of 5 stars$17.72-4.6%$27.33+54.3%N/A$953.80M$59.81M0.00300News CoveragePositive NewsLockup ExpirationINMDInMode3.7761 of 5 stars$14.57-1.6%$18.04+23.8%-10.6%$936.13M$394.82M5.90480News CoveragePositive NewsIRMDiRadimed4.8367 of 5 stars$71.50-1.6%$72.00+0.7%+54.3%$924.23M$73.24M44.14110News CoveragePositive NewsEMBCEmbecta4.6266 of 5 stars$14.26-0.8%$19.00+33.2%-11.4%$841.02M$1.12B9.972,100Positive NewsTNDMTandem Diabetes Care4.6683 of 5 stars$12.11+1.5%$22.47+85.5%-71.2%$806.10M$940.20M-3.922,650Positive NewsShort Interest ↓AXGNAxoGen3.0435 of 5 stars$14.79-9.0%$26.00+75.8%+22.7%$748.16M$187.34M-147.89450News CoverageShort Interest ↓Gap DownBBNXBeta BionicsN/A$17.45+2.3%$22.56+29.3%N/A$741.17M$65.12M0.00294News CoverageSIBNSiBone4.0975 of 5 stars$16.05-2.1%$23.67+47.5%+0.3%$707.08M$167.18M-28.66350 Related Companies and Tools Related Companies Pulse Biosciences Alternatives MiMedx Group Alternatives Kestra Medical Technologies Alternatives InMode Alternatives iRadimed Alternatives Embecta Alternatives Tandem Diabetes Care Alternatives AxoGen Alternatives Beta Bionics Alternatives SiBone Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NPCE) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NPCE Stock Alerts